Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HROW 
Harrow Health Inc (HROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: HROW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $70.62
1 Year Target Price $70.62
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 41.67% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49B USD | Price to earnings Ratio - | 1Y Target Price 70.62 |
Price to earnings Ratio - | 1Y Target Price 70.62 | ||
Volume (30-day avg) 5 | Beta 0.07 | 52 Weeks Range 20.85 - 50.72 | Updated Date 12/2/2025 |
52 Weeks Range 20.85 - 50.72 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-10 | When - | Estimate 0.24 | Actual 0.33 |
Profitability
Profit Margin -2% | Operating Margin (TTM) 20.58% |
Management Effectiveness
Return on Assets (TTM) 4.91% | Return on Equity (TTM) -9.57% |
Valuation
Trailing PE - | Forward PE 38.76 | Enterprise Value 1725006786 | Price to Sales(TTM) 5.95 |
Enterprise Value 1725006786 | Price to Sales(TTM) 5.95 | ||
Enterprise Value to Revenue 6.9 | Enterprise Value to EBITDA 43.8 | Shares Outstanding 37037453 | Shares Floating 27264380 |
Shares Outstanding 37037453 | Shares Floating 27264380 | ||
Percent Insiders 15.7 | Percent Institutions 58.13 |
Upturn AI SWOT
Harrow Health Inc
Company Overview
History and Background
Harrow Health, Inc. (HROW) was founded in 2014 and is headquartered in Nashville, Tennessee. It operates as a pharmaceutical company focused on acquiring, developing, and commercializing ophthalmic pharmaceutical products. The company initially focused on compounding pharmacies but has transitioned towards branded prescription pharmaceuticals.
Core Business Areas
- ImprimisRx: Focuses on providing compounded medications, primarily for ophthalmic use.
- NDC: Specializes in branded ophthalmic pharmaceuticals, including IHEEZO.
- Surface: Offers branded pharmaceuticals focused on ocular surface diseases.
- Visionology: A platform dedicated to supporting eye care professionals and their patients with innovative solutions and services.
Leadership and Structure
Mark L. Baum serves as the Chief Executive Officer. The company has a board of directors and operates with functional departments covering research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- IHEEZO: A branded ophthalmic solution containing chloroprocaine hydrochloride for corneal anesthesia. IHEEZO is Harrow's primary branded product and faces competition from generic anesthetics and other branded ocular anesthetics. Specific market share data is difficult to obtain as the market is fragmented, but IHEEZO is growing significantly. Competitors include proparacaine and tetracaine ophthalmic solutions, as well as Akorn, Bausch + Lomb and Novartis when those companies offer comparable products.
- Compounded Pharmaceuticals: Harrow provides a wide range of compounded ophthalmic medications through ImprimisRx. These medications address specific patient needs and often fill gaps in the availability of commercially manufactured products. The market for compounded medications is fragmented and highly competitive, with numerous compounding pharmacies competing for market share. It is harder to give specific market share or revenue data on the compounded product as it is fragmented.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is characterized by increasing demand due to an aging population and rising prevalence of eye diseases. The industry includes branded and generic pharmaceuticals, as well as compounded medications. It's a high-growth space driven by innovation and demographic trends.
Positioning
Harrow Health occupies a niche position, focusing on branded pharmaceuticals and compounded medications for ophthalmology. Their strategy involves acquiring or developing niche products and offering customized solutions through ImprimisRx. Their competitive advantage lies in their specialized focus and ability to address unmet patient needs.
Total Addressable Market (TAM)
The global ophthalmic market is estimated to be over $40 billion. Harrow Health targets specific segments within this market, including ocular anesthesia and ocular surface disease. The TAM for their targeted products is substantial, representing a significant growth opportunity.
Upturn SWOT Analysis
Strengths
- Specialized focus on ophthalmology
- Ability to acquire and commercialize niche products
- Strong compounding pharmacy capabilities
- Experienced management team
Weaknesses
- Reliance on acquisitions for growth
- Relatively small size compared to major pharmaceutical companies
- Dependence on a few key products
- Significant debt load
Opportunities
- Expanding product portfolio through acquisitions or internal development
- Increasing demand for ophthalmic pharmaceuticals
- Potential to enter new geographic markets
- Strategic partnerships with other companies
Threats
- Competition from larger pharmaceutical companies
- Generic competition
- Changes in regulations
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- ALC
- VRX
- JNJ
Competitive Landscape
Harrow Health faces competition from larger pharmaceutical companies with more extensive resources and broader product portfolios. However, Harrow's specialized focus and niche product strategy allow it to compete effectively in targeted market segments. Harrow is focused on growing faster than its competitors.
Major Acquisitions
Eton Pharmaceuticals' Ophthalmic Products
- Year: 2022
- Acquisition Price (USD millions): 45
- Strategic Rationale: Expanded Harrow Health's product portfolio and pipeline in the ophthalmic market.
Mitotech S.A.
- Year: 2023
- Acquisition Price (USD millions): 28.5
- Strategic Rationale: Added SkQ1 asset for dry eye disease.
Growth Trajectory and Initiatives
Historical Growth: Harrow Health has experienced substantial revenue growth in recent years, primarily driven by acquisitions and the successful commercialization of key products.
Future Projections: Analyst estimates suggest continued revenue growth for Harrow Health, driven by increasing sales of IHEEZO and other branded products. Profitability is expected to improve as the company achieves greater economies of scale.
Recent Initiatives: Recent initiatives include the launch and promotion of IHEEZO, strategic acquisitions, and investments in research and development.
Summary
Harrow Health is a growing ophthalmic pharmaceutical company with a niche focus on branded products and compounded medications. The company has demonstrated strong revenue growth through acquisitions and successful product commercialization. However, it faces competition from larger players and must carefully manage its debt levels. Overall, Harrow Health's growth is promising, but it will need to be strategic to maintain its position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Presentations
- Analyst Reports
- Company Website
- Yahoo Finance
- Bloomberg
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available sources. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harrow Health Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2007-09-28 | CEO & Chairman of the Board Mr. Mark L. Baum J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 382 | Website https://www.harrow.com |
Full time employees 382 | Website https://www.harrow.com | ||
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.